Ibrahim M Dighriri, Shahad Nazel, Aeshah M Alharthi, Nasreen A Altowairqi, Aqeel M Albariqi, Mona A Tohari, Atheer A Alameer, Amjad K Alsaran, Fares R ALshammari, Naif F AlMutairi, Fahad M Alsubaie, Turki A Alharbi
Ubrogepant is an innovative medication designed for the acute treatment of migraine, a debilitating neurological condition that profoundly impairs quality of life, productivity, and social interactions. This comprehensive review assesses the efficacy, safety, tolerability, and mechanism of action of ubrogepant through a rigorous methodology, including an in-depth literature review from reputable databases like PubMed, Web of Science, Embase, Scopus, and Cochrane. Classified as a calcitonin gene-related peptide (CGRP) receptor antagonist, ubrogepant has emerged as a potential revolutionary medication for migraine treatment...
November 2023: Curēus